Sandoz: Biosimilars Company Analysis

Introduction

Abstract

Analysis of Sandoz's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

INTRODUCTION

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.

FEATURES AND BENEFITS

• Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
• Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.

HIGHLIGHTS

• Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars in its portfolio including nine biosimilars in development.

YOUR KEY QUESTIONS ANSWERED

• See how Sandoz became the first generics company to gain approval for a biosimilar product
• Evaluate the firm's wide variety of biosimilars in its portfolio, including nine biosimilars in development

Table of Contents

ABOUT THIS REPORT

• CHAPTER STRUCTURE
  • Executive summary
  • Strategic insight
  • Product analysis
  • Operating performance
  • Company introduction
• DATA SOURCING
  • Sales data
  • Analyst consensus
• PharmaVitae explorer database

EXECUTIVE SUMMARY

• Sandoz biosimilars overview
• Sandoz biosimilars infrastructure

STRATEGIC INSIGHT

• Sandoz biosimilars SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
• Sandoz has focused on producing difficult-to-make biosimilars with the greatest sales potential
• Aggressive M&A strategy has given Sandoz a strong market position
  • However, its biosimilar portfolio is difficult to value

KEY PRODUCTS

• Overview
• Sandoz biosimilar portfolio
• Omnitrope
  • Overview
  • Somatropin market sizing
  • Key competitors
  • Sandoz biosimilar development
  • Clinical trials
• Binocrit
  • Overview
  • Erythropoietin market sizing
  • Key competitors
  • Sandoz biosimilar development
  • Clinical trials
• Zarzio
  • Overview
  • Filgrastim market sizing
  • Key competitors
  • Sandoz biosimilar development
  • Clinical trials
• GP2013
  • Overview
  • Rituximab market sizing
  • Key competitors
  • Sandoz biosimilar development
  • Clinical trials

OPERATING PERFORMANCE

• Operating costs and profit analysis
  • Operating costs and profit analysis, 2004-16
  • Operating cost ratio and profit margin analysis, 2004-16

CORPORATE STRUCTURE

• Key findings
• CORPORATE RELATIONSHIPS
• Recent developments

APPENDIX

• REFERENCES
• EXCHANGE RATES

• Table: Sandoz - manufacturing and development metrics
• Table: Sandoz - biosimilar portfolio
• Table: Forecast somatropin sales ($m), 2011-16
• Table: Biosimilar somatropin drugs, 2012
• Table: Sandoz biosimilar Omnitrope clinical trials
• Table: Forecast epoetin and darbepoetin sales ($m), 2011-16
• Table: Biosimilar epoetin drugs, 2012
• Table: Sandoz biosimilar erythropoietin clinical trials
• Table: Forecast filgrastim and pegfilgrastim sales ($m), 2011-16
• Table: Biosimilar filgrastim drugs, 2012
• Table: Biosimilar pegfilgrastim drugs, 2012
• Table: Sandoz biosimilar filgrastim clinical trials
• Table: Forecast MabThera sales ($m), 2011-16
• Table: Biosimilar rituximab drugs, 2012
• Table: Sandoz biosimilar GP2013 clinical trials
• Table: Sandoz operating revenues, costs, and profit ($m), 2004-10
• Table: Sandoz operating revenues, costs, and profit ($m), 2010-16
• Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2004-10
• Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2010-16
• Table: Sandoz - deal activity and biosimilar deals
• Table: Exchange rates, 2011

• Figure: The PharmaVitae Explorer
• Figure: Sandoz biosimilars overview
• Figure: Sandoz operating revenues, costs, and profit ($m), 2004-16
• Figure: Sandoz - revenue by geographic region, 2011
• Figure: Sandoz - revenue by segment, 2011

Sandoz: Biosimilars Company Analysis published by Datamonitor in July 6, 2012. This report consists of Pages: 37 and the price starts from US $ 3800.